Back

Targeting ligand binding sites in Plasmodium falciparum NCR1 enables antimalarial drug discovery

Kohling, A.; Boulet, C.; Al Makhlouf, M.; Khanppnavar, B.; Chen, Y.; Ganga, E.; Kirchmair, J.; Stockner, T.; Brochet, M.; Korkhov, V. M.

2025-11-11 biochemistry
10.1101/2025.11.11.687791 bioRxiv
Show abstract

PfNCR1 is a Plasmodium falciparum cholesterol transporter at the plasma membrane- parasitophorous vacuole interface, which has recently emerged as a promising antimalarial target. Despite an immense interest in development of novel antimalarials targeting PfNCR1, the molecular mechanism of PfNCR1 inhibition remains elusive. Here, we report cryo-EM structures of PfNCR1 in its apo state and bound to three inhibitors: MMV009108, MMV019662 and MMV028038. MMV009108 binds to the "neck" site at the ectodomain-membrane domain interface. MMV028038 displaces the sterol at the ectodomain "ecto" site. Remarkably, MMV019662 binds both sites: it associates near the bound sterol molecule at the ecto site and targets the neck site, thereby altering the sterol-sensing domain conformation. Moreover, we identify a novel antimalarial compound, G856-4236, which targets the ecto site exclusively. These four distinct modes of PfNCR1 inhibition advance our understanding of its conformational plasticity and establish a framework for rational drug discovery targeting PfNCR1 and related transporters.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.